Literature DB >> 23479674

Thermodynamic stability of domain III from the envelope protein of flaviviruses and its improvement by molecular design.

Nora Zidane1, Philippe Dussart, Laetitia Bremand, Maria Elena Villani, Hugues Bedouelle.   

Abstract

The Flavivirus genus includes widespread and severe human pathogens like the four serotypes of dengue virus (DENV1 to DENV4), yellow fever virus, Japanese encephalitis virus and West Nile virus. Domain III (ED3) of the viral envelope protein interacts with cell receptors and contains epitopes recognized by virus neutralizing antibodies. Its structural, antigenic and immunogenic properties have been thoroughly studied contrary to its physico-chemical properties. Here, the ED3 domains of the above pathogenic flaviviruses were produced in the periplasm of Escherichia coli. Their thermodynamic stabilities were measured and compared in experiments of unfolding equilibriums, induced with chemicals or heat and monitored through protein fluorescence. A designed ED3 domain, with the consensus sequence of DENV strains from all serotypes, was highly stable. The low stability of the ED3 domain from DENV3 was increased by three changes of residues in the protein core without affecting its reactivity towards DENV-infected human serums. Additional changes showed that the stability of ED3 varied with the DENV3 genotype. The T(m) of ED3 was higher than 69°C for all the tested viruses and reached 86°C for the consensus ED3. The latter, deprived of its disulfide bond by mutations, was predominantly unfolded at 20°C. These results will help better understand and design the properties of ED3 for its use as diagnostic, vaccine or therapeutic tools.

Entities:  

Keywords:  antigenicity; consensus sequence; envelope protein; flavivirus; protein stability

Mesh:

Substances:

Year:  2013        PMID: 23479674     DOI: 10.1093/protein/gzt010

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  7 in total

1.  Designing multivalent immunogens for alphavirus vaccine optimization.

Authors:  C M Read; Kenneth Plante; Grace Rafael; Shannan L Rossi; Werner Braun; Scott C Weaver; Catherine H Schein
Journal:  Virology       Date:  2021-02-05       Impact factor: 3.513

2.  Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus.

Authors:  Indira S Harahap-Carrillo; Ivonne Ceballos-Olvera; Jorge Reyes-Del Valle
Journal:  Vaccines (Basel)       Date:  2015-07-03

Review 3.  Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections.

Authors:  Xingcui Zhang; Renyong Jia; Haoyue Shen; Mingshu Wang; Zhongqiong Yin; Anchun Cheng
Journal:  Viruses       Date:  2017-11-13       Impact factor: 5.048

4.  The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study.

Authors:  Heidi Auerswald; Leonard Klepsch; Sebastian Schreiber; Janne Hülsemann; Kati Franzke; Simone Kann; Bunthin Y; Veasna Duong; Philippe Buchy; Michael Schreiber
Journal:  Viruses       Date:  2019-03-27       Impact factor: 5.048

5.  Computational and Rational Design of Single-Chain Antibody against Tick-Borne Encephalitis Virus for Modifying Its Specificity.

Authors:  Ivan K Baykov; Pavel Y Desyukevich; Ekaterina E Mikhaylova; Olga M Kurchenko; Nina V Tikunova
Journal:  Viruses       Date:  2021-07-29       Impact factor: 5.048

6.  Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.

Authors:  Nora Zidane; Philippe Dussart; Laetitia Bremand; Hugues Bedouelle
Journal:  BMC Infect Dis       Date:  2013-07-01       Impact factor: 3.090

7.  Establishment and Comparison of Two Different Diagnostic Platforms for Detection of DENV1 NS1 Protein.

Authors:  Yin-Liang Tang; Chien-Yu Chiu; Chun-Yu Lin; Chung-Hao Huang; Yen-Hsu Chen; Raul V Destura; Day-Yu Chao; Han-Chung Wu
Journal:  Int J Mol Sci       Date:  2015-11-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.